Oral and injectable GLP-1 medicines: what is different

GLP-1 medicines come as weekly or daily injections and as daily tablets. Route, formulation, labeled uses and instructions differ by product, so the label for your exact medicine is the guide. Trials of tablets and injections were run separately, so their results cannot be compared directly.

Quick answer

GLP-1 medicines come as weekly or daily injections and as daily tablets. Route, formulation, labeled uses and instructions differ by product, so the label for your exact medicine is the guide. Trials of tablets and injections were run separately, so their results cannot be compared directly.

What differs between products

  • Route and form. Wegovy has injection and tablet presentations, while Zepbound is an injection. Semaglutide tablets are also labeled as Rybelsus and Ozempic tablets for type 2 diabetes. Check the exact product label for its route, use and instructions; the presentations are not interchangeable.
  • Administration conditions. The Rybelsus label sets specific conditions for taking the tablet, covering food, water and waiting time, and gives its own missed-dose direction. Injectable labels have their own, different directions. This page does not restate them. Read the label and Medication Guide for your product, and ask your pharmacist or clinician. Sources: Rybelsus label Wegovy label Zepbound label.
  • Storage. Storage rules are product-specific and are on each label.
  • Labeled uses and warnings. Each label lists its own indications, contraindications and boxed warnings. Do not assume they match.

What the trials show

Oral semaglutide (OASIS 4) and injected semaglutide (STEP 1)

Oral semaglutide (OASIS 4) and injected semaglutide (STEP 1)

In OASIS 4, adults with obesity or overweight and no diabetes took oral semaglutide 25 mg or placebo for 64 weeks (71-week trial). Mean weight change was -13.6% versus -2.2%. Source: OASIS 4, NEJM 2025. In STEP 1, injected semaglutide 2.4 mg weekly produced a mean change of -14.9% versus -2.4% over 68 weeks. Source: STEP 1, NEJM 2021.

These are separate trials with different participants, lengths and designs. Putting the two bars side by side shows each result, not which route is better.

When trials compare routes directly

Only a trial that randomizes people to a tablet versus an injection can compare them. This page does not cite one. Indirect comparison across trials cannot show a difference in effect or side effects.

Questions to bring to your clinician

  • Which products are appropriate for my situation, and which does my plan cover?
  • Do I have conditions or medicines that affect the choice (see each label’s contraindications and warnings)?
  • Can I follow the administration conditions in the label?
  • What side effects should I watch for, and who do I contact?

What this does not establish

Neither trial tested one route against the other. Results apply to the doses, populations and timeframes studied. Availability, indications and labels change, so recheck on the publication date.

FAQs

What is the difference between oral and injectable GLP-1 medicines? Form, administration conditions, storage and labeling. Each product’s label is the source for these.

What does human research show? Separate trials of oral and injected semaglutide each showed greater average weight loss than placebo. They were not head-to-head.

What safety questions remain? Long-term comparisons between routes, and which product suits which person. These are for your clinician and the current label.

Sources

  1. OASIS 4, N Engl J Med 2025
  2. STEP 1, N Engl J Med 2021
  3. Rybelsus label
  4. Wegovy label
  5. Zepbound label, Lilly

Source methods and reading limits

Sources checked against Europe PMC abstracts and product-label text: November 17, 2026. Full text was not read for abstract-only claims. Source dates and reading limits are recorded with the supporting references.